D.A. Davidson & CO. Raises Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

D.A. Davidson & CO. grew its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 36.4% during the fourth quarter, Holdings Channel reports. The institutional investor owned 11,907 shares of the medical equipment provider’s stock after buying an additional 3,175 shares during the period. D.A. Davidson & CO.’s holdings in Zimmer Biomet were worth $1,258,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently made changes to their positions in ZBH. CKW Financial Group increased its stake in Zimmer Biomet by 11.7% in the 4th quarter. CKW Financial Group now owns 955 shares of the medical equipment provider’s stock worth $101,000 after buying an additional 100 shares in the last quarter. FWG Holdings LLC lifted its position in shares of Zimmer Biomet by 2.9% in the third quarter. FWG Holdings LLC now owns 3,591 shares of the medical equipment provider’s stock valued at $372,000 after acquiring an additional 101 shares in the last quarter. Romano Brothers AND Company boosted its stake in shares of Zimmer Biomet by 1.1% in the fourth quarter. Romano Brothers AND Company now owns 9,466 shares of the medical equipment provider’s stock worth $1,000,000 after acquiring an additional 102 shares during the period. Financial Advocates Investment Management grew its position in shares of Zimmer Biomet by 3.5% during the third quarter. Financial Advocates Investment Management now owns 3,053 shares of the medical equipment provider’s stock worth $330,000 after purchasing an additional 103 shares in the last quarter. Finally, Modera Wealth Management LLC raised its stake in Zimmer Biomet by 1.6% during the 3rd quarter. Modera Wealth Management LLC now owns 7,496 shares of the medical equipment provider’s stock valued at $809,000 after purchasing an additional 120 shares during the period. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Trading Up 1.2 %

NYSE:ZBH opened at $104.89 on Monday. The stock has a market capitalization of $20.88 billion, a price-to-earnings ratio of 23.57, a PEG ratio of 1.95 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 52 week low of $97.69 and a 52 week high of $133.90. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The firm has a 50 day moving average of $105.86 and a 200 day moving average of $107.46.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, topping analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the previous year, the business posted $2.20 earnings per share. As a group, sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Monday, December 30th were given a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.92%. The ex-dividend date was Monday, December 30th. Zimmer Biomet’s payout ratio is currently 21.57%.

Wall Street Analysts Forecast Growth

ZBH has been the subject of several recent analyst reports. Stifel Nicolaus upped their price target on Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a research note on Thursday, January 23rd. Truist Financial restated a “hold” rating and set a $113.00 target price (down previously from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th. JMP Securities reiterated a “market outperform” rating and issued a $140.00 price target on shares of Zimmer Biomet in a report on Friday, February 7th. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a report on Friday, February 7th. Finally, Barclays reduced their target price on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a report on Monday, February 10th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $124.15.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.